Bofu-Tsu-Shosan, an Oriental Herbal Medicine, Exerts a Combinatorial Favorable Metabolic Modulation Including Antihypertensive Effect on a Mouse Model of Human Metabolic Disorders with Visceral Obesity

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Azushima, Kengo ^a   Tamura, Kouichi ^a   Wakui, Hiromichi ^a   Maeda, Akinobu ^a   Ohsawa, Masato ^a   Uneda, Kazushi ^a   Kobayashi, Ryu ^a   Kanaoka, Tomohiko ^a   Dejima, Toru ^a   Fujikawa, Tetsuya ^a   Yamashita, Akio ^a   Toya, Yoshiyuki ^a   Umemura, Satoshi ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BOFU TSU SHOSAN; GHRELIN; HERBACEOUS AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMA ACYLATED GHRELIN; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BROWN ADIPOSE TISSUE; CELL SIZE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; FOOD INTAKE; GENE EXPRESSION; HEART RATE; HERBAL MEDICINE; HYPERTENSION; INTRAABDOMINAL FAT; LONG TERM CARE; MALE; METABOLIC DISORDER; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; RECTUM TEMPERATURE; SYSTOLIC BLOOD PRESSURE; TISSUES; VISCERAL OBESITY; WEIGHT GAIN; WHITE ADIPOSE TISSUE;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; HERBAL MEDICINE; HUMANS; ION CHANNELS; METABOLIC DISEASES; MICE; MITOCHONDRIAL PROTEINS; OBESITY, ABDOMINAL;

EID: 84885168967     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075560     Document Type: Article

References (40)

1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645.
2. Strazzullo P, D'Elia L, Cairella G, Garbagnati F, Cappuccio FP, et al. (2010) Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke 41: e418-426.
3. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, et al. (2011) Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 6: 2364-2373.
4. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373: 1083-1096.
5. Goodpaster BH, Delany JP, Otto AD, Kuller L, Vockley J, et al. (2010) Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA 304: 1795-1802.
6. Horvath K, Jeitler K, Siering U, Stich AK, Skipka G, et al. (2008) Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Arch Intern Med 168: 571-580.
7. Dietrich MO, Horvath TL, (2012) Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat Rev Drug Discov 11: 675-691.
8. Maggs FG, (2012) Problem based review: the morbidly obese patient. Acute Med 11: 107-112.
9. Yoshida T, Sakane N, Wakabayashi Y, Umekawa T, Kondo M, (1995) Thermogenic, anti-obesity effects of bofu-tsusho-san in MSG-obese mice. Int J Obes Relat Metab Disord 19: 717-722.
10. Hioki C, Yoshimoto K, Yoshida T, (2004) Efficacy of bofu-tsusho-san, an oriental herbal medicine, in obese Japanese women with impaired glucose tolerance. Clin Exp Pharmacol Physiol 31: 614-619.
11. Morimoto Y, Sakata M, Ohno A, Maegawa T, Tajima S, (2001) [Effects of bofu-tsusho-san, a traditional Chinese medicine, on body fat accumulation in fructose-loaded rats]. Nihon Yakurigaku Zasshi 117: 77-86.
12. Morimoto Y, Sakata M, Ohno A, Maegawa T, Tajima S, (2002) [Effects of Byakko-ka-ninjin-to, Bofu-tsusho-san and Gorei-san on blood glucose level, water intake and urine volume in KKAy mice]. Yakugaku Zasshi 122: 163-168.
13. Nakayama T, Suzuki S, Kudo H, Sassa S, Nomura M, et al. (2007) Effects of three Chinese herbal medicines on plasma and liver lipids in mice fed a high-fat diet. J Ethnopharmacol 109: 236-240.
14. Sakamoto S, Takeshita S, Sassa S, Suzuki S, Ishikawa Y, et al. (2005) Effects of colestimide and/or Bofu-tsusho-san on plasma and liver lipids in mice fed a high-fat diet. In Vivo 19: 1029-1033.
15. Akagiri S, Naito Y, Ichikawa H, Mizushima K, Takagi T, et al. (2008) Bofutsushosan, an oriental herbal medicine, attenuates the weight gain of white adipose tissue and the increased size of adipocytes associated with the increase in their expression of uncoupling protein 1 in high-fat diet-fed male KK/Ta mice. J Clin Biochem Nutr 42: 158-166.
16. Iwamoto T, Kita S, Zhang J, Blaustein MP, Arai Y, et al. (2004) Salt-sensitive hypertension is triggered by Ca2+ entry via Na+/Ca2+ exchanger type-1 in vascular smooth muscle. Nat Med 10: 1193-1199.
17. Tsurumi Y, Tamura K, Tanaka Y, Koide Y, Sakai M, et al. (2006) Interacting molecule of AT1 receptor, ATRAP, is colocalized with AT1 receptor in the mouse renal tubules. Kidney Int 69: 488-494.
18. Wakui H, Tamura K, Matsuda M, Bai Y, Dejima T, et al. (2010) Intrarenal suppression of angiotensin II type 1 receptor binding molecule in angiotensin II-infused mice. Am J Physiol Renal Physiol 299: F991-F1003.
19. Matsuda M, Tamura K, Wakui H, Dejima T, Maeda A, et al. (2011) Involvement of Runx3 in the basal transcriptional activation of the mouse angiotensin II type 1 receptor-associated protein gene. Physiol Genomics 43: 884-894.
20. Wakui H, Tamura K, Tanaka Y, Matsuda M, Bai Y, et al. (2010) Cardiac-specific activation of angiotensin II type 1 receptor-associated protein completely suppresses cardiac hypertrophy in chronic angiotensin II-infused mice. Hypertension 55: 1157-1164.
21. Uno K, Yamada T, Ishigaki Y, Imai J, Hasegawa Y, et al. (2012) Hepatic peroxisome proliferator-activated receptor-gamma-fat-specific protein 27 pathway contributes to obesity-related hypertension via afferent vagal signals. Eur Heart J 33: 1279-1289.
22. Desvergne B, Wahli W, (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688.
23. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, et al. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094-2099.
24. Rosen ED, Spiegelman BM, (2001) PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731-37734.
25. Hiuge A, Tenenbaum A, Maeda N, Benderly M, Kumada M, et al. (2007) Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 27: 635-641.
26. Qiao L, Lee B, Kinney B, Yoo HS, Shao J, (2011) Energy intake and adiponectin gene expression. Am J Physiol Endocrinol Metab 300: E809-816.
27. Dorresteijn JA, Visseren FL, Spiering W, (2012) Mechanisms linking obesity to hypertension. Obes Rev 13: 17-26.
28. Wang ZV, Scherer PE, (2008) Adiponectin, cardiovascular function, and hypertension. Hypertension 51: 8-14.
29. Yiannikouris F, Gupte M, Putnam K, Cassis L, (2010) Adipokines and blood pressure control. Curr Opin Nephrol Hypertens 19: 195-200.
30. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, et al. (2006) Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47: 1108-1116.
31. Takemori K, Kimura T, Shirasaka N, Inoue T, Masuno K, et al. (2011) Food restriction improves glucose and lipid metabolism through Sirt1 expression: a study using a new rat model with obesity and severe hypertension. Life Sci 88: 1088-1094.
32. Zhu M, Miura J, Lu LX, Bernier M, DeCabo R, et al. (2004) Circulating adiponectin levels increase in rats on caloric restriction: the potential for insulin sensitization. Exp Gerontol 39: 1049-1059.
33. Dolinsky VW, Morton JS, Oka T, Robillard-Frayne I, Bagdan M, et al. (2010) Calorie restriction prevents hypertension and cardiac hypertrophy in the spontaneously hypertensive rat. Hypertension 56: 412-421.
34. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, et al. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656-660.
35. Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, et al. (2002) The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123: 1120-1128.
36. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, et al. (2000) Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology 141: 4797-4800.
37. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, et al. (2001) A role for ghrelin in the central regulation of feeding. Nature 409: 194-198.
38. Seoane LM, Lopez M, Tovar S, Casanueva FF, Senaris R, et al. (2003) Agouti-related peptide, neuropeptide Y, and somatostatin-producing neurons are targets for ghrelin actions in the rat hypothalamus. Endocrinology 144: 544-551.
39. van der Lely AJ, Tschop M, Heiman ML, Ghigo E, (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25: 426-457.
40. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, et al. (2000) The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141: 4325-4328.